Author:
Ohzeki Takayuki,Adomi Shogo,Koike Hiroyuki,Esa Atsunobu,Fukuda Syoichi,Yamada Yuji
Publisher
Japanese Urological Association
Reference13 articles.
1. 1) D'Amico A.V., Whittington R., Malkowicz SB., Schultz D., Blank K., Broderick GA., Tomaszewski JE., Renshaw AA., Kaplan I., Beard CJ. and Wein A.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280, 969-974, 1998.
2. 2) Dearnaley DP., Sydes MR., Graham JD., Aird EG., Bottomley D., Cowan RA., Huddart RA., Jose CC., Matthews JH., Millar J., Moore AR., Morgan RC., Russell JM., Scrase CD., Stephens RJ., Syndikus I. and Parmar MK.: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol., 8, 475-487, 2007.
3. 3) Kuban DA., Tucker SL., Dong L., Starkschall G., Huang EH., Cheung MR., Lee AK. and Pollack A.: Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 70, 67-74, 2008.
4. 4) NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer (Version 1.2011.) at NCCN org URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#prostate
5. 5) Cahlon O., Zelefsky MJ., Shippy A., Chan H., Fuks Z., Yamada Y., Hunt M., Greenstein S. and Amols H.: Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys, 71, 330-337, 2008.